Probing the Bioactive Constituents from Chemotypes of the Sponge Psammocinia aff. bulbosa

Sarah J. Robinson, Karen Tenney, Desiree F. Yee, Lizabeth Martinez, Joseph E. Media, Frederick A. Valeriote, Rob W. M. van Soest,§ and Phillip Crews*
Department of Chemistry and Biochemistry and Institute for Marine Sciences, University of California, Santa Cruz, Santa Cruz, California 95064, Josephine Ford Cancer Center, Henry Ford Health System, Detroit, Michigan 48202, and Zologisch Museum, University of Amsterdam, P.O. Box 94766, 1090 GT, Amsterdam, The Netherlands
J. Nat. Prod., 2007, 70 (6), pp 1002–1009
DOI: 10.1021/np070171i
Publication Date (Web): June 9, 2007
Copyright © 2007 American Chemical Society and American Society of Pharmacognosy

 University of California, Santa Cruz.

,

 Josephine Ford Cancer Center.

,
§

 University of Amsterdam.

,
*

 To whom correspondence should be addressed. Tel:  831-459-2603. Fax:  831-459-2935. E-mail:  phil@chemistry.ucsc.edu.

Abstract

Abstract Image

Since the report of (+)-psymberin (2) in 2004, many synthetic groups have pursued the synthesis of this compound, and our group has further collected Psammocinia aff. bulbosa to successfully isolate more 2. With more (+)-psymberin (2) in hand, additional clonogenic studies, a therapeutic efficacy assessment, and the hollow fiber assay have been completed. The inconsistent production of (+)-psymberin (2) and the classification of six Psammocinia species are further discussed herein. The most recent of these six collections resulted in the isolation of a new brominated cyclic peptide, (−)-psymbamide A (4), which is the first report of a Psammocinia-derived compound in this peptide class. The planar structure was solved via dereplication with Marinlit, HRESIMS, and 1D and 2D NMR techniques, and the absolute configuration determined using Marfey's method.

Tools

History

  • Published In Issue June 22, 2007
  • Received April 13, 2007

Recommend & Share

Related Content

Other ACS content by these authors: